2 completed, 1 active not recruiting, 1 terminated. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
Follow Tazobactam: new trials by email Literature Review of Tazobactam trials Research Report on Tazobactam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients Meropenem I.V. 2g as a 3 hour infusion every 8 hours, Tazocin (pipercillin/tazobactam) - Sepsis | Phase 1 / Phase 2 | Active not recruiting | Ain Shams University | 400 | 2024-01-01 | 2025-10-03 |
| A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%, piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%, piperacillin 2% + tazobactam 0.25% - Otitis Media, Otorrhea | Phase 1 / Phase 2 | Terminated | Yuhan Corporation | 135 | 2016-06-01 | 2022-01-13 |
| Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007) Ceftolozane/Tazobactam - Multiple Doses, Ceftolozane/Tazobactam - Single Dose - Critically Ill, Pneumonia | Phase 1 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 37 | 2015-02-05 | 2019-08-28 |
| Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010) Ceftolozane/Tazobactam 1000/500 mg, Ceftolozane/Tazobactam 30/15 mg/kg, Ceftolozane/Tazobactam 20/10 mg/kg - Proven or Suspected Gram-negative Bacterial Infection, Peri-operative Prophylaxis | Phase 1 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 43 | 2014-09-17 | 2019-09-11 |
Burns (1) · Critical Illness (1) · Otitis Media (1) · Pneumonia (1) · Sepsis (1)
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · Ain Shams University (1) · Yuhan Corporation (1)
Egypt (1) · South Korea (1)
Aya A Bayoumy, MD (1) · Mohamed A Ali, MD (1) · Osama R Abdelmalek, MD (1) · Thabet A Botros, MD (1)
PMID 30153232, PMID 32211756, PMID 33567333
2014 (1)